• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

匈牙利类风湿性关节炎患者长期护理的经济负担。

Economic burden of long-term care of rheumatoid arthritis patients in Hungary.

机构信息

Institute for Health Insurance, Faculty of Health Sciences, University of Pécs, Mária u. 5-7, 7621, Pécs, Hungary.

出版信息

Eur J Health Econ. 2014 May;15 Suppl 1:S131-5. doi: 10.1007/s10198-014-0601-9. Epub 2014 May 16.

DOI:10.1007/s10198-014-0601-9
PMID:24832843
Abstract

BACKGROUND AND AIM

Long-term care (LTC) in Hungary is provided in four major ways: day care, nursing, chronic care, and rehabilitation. The aim of this study was to explore the financing of LTC in Hungary, with a disease-specific focus on rheumatoid arthritis (RA) patients.

DATA AND METHODS

Data were derived from the National Health Insurance Fund Administration (NHIFA). For 2012, we analyzed the following indicators: number of patients and cases, crude and weighted hospital days, and health insurance expenditure.

RESULTS

The annual health insurance expenditure of LTC was 112.6 million EUR in Hungary in 2012 and covered 209,000 patients (225,000 cases). The NHIFA spent 0.69 million EUR for the LTC of 976 patients with RA. The annual health insurance cost per patient was significantly (by 32%) higher for patients with RA (710 EUR) than the average cost of all patients (538 EUR). The average length of stay was also higher for patients with RA (19.7 days) than for the general LTC population (17.4 days).

CONCLUSIONS

The cost of LTC of patients with RA is higher than the average cost of the general LTC patient population. Early treatment of RA patients could contribute to decreasing LTC expenditure. More generally, health technology assessment can inform future LTC funding debates in Central and Eastern European countries by putting more emphasis on LTC utilization and costs.

摘要

背景与目的

匈牙利有四种主要的长期护理(LTC)方式:日间护理、护理、慢性病护理和康复。本研究旨在探讨匈牙利的 LTC 融资情况,特别关注类风湿关节炎(RA)患者。

数据和方法

数据来自国家健康保险基金管理局(NHIFA)。我们分析了 2012 年的以下指标:患者和病例数量、未加权和加权住院天数以及医疗保险支出。

结果

2012 年,匈牙利 LTC 的年医疗保险支出为 1.126 亿欧元,覆盖了 20.9 万名患者(22.5 万例)。NHIFA 为 976 名 RA 患者的 LTC 支出了 0.69 万欧元。RA 患者的年人均医疗保险费用(710 欧元)明显高于所有患者的平均费用(538 欧元),高出 32%。RA 患者的平均住院天数也高于一般 LTC 人群(19.7 天)。

结论

RA 患者的 LTC 成本高于一般 LTC 患者人群的平均成本。早期治疗 RA 患者可有助于降低 LTC 支出。更广泛地说,卫生技术评估可以通过更加强调 LTC 的利用和成本,为中东欧国家的未来 LTC 融资辩论提供信息。

相似文献

1
Economic burden of long-term care of rheumatoid arthritis patients in Hungary.匈牙利类风湿性关节炎患者长期护理的经济负担。
Eur J Health Econ. 2014 May;15 Suppl 1:S131-5. doi: 10.1007/s10198-014-0601-9. Epub 2014 May 16.
2
[Nationwide epidemiological and health insurance disease burden of rheumatoid arthritis in Hungary].[匈牙利类风湿关节炎的全国性流行病学及健康保险疾病负担]
Orv Hetil. 2021 Mar 28;162(162 Suppl 1):30-37. doi: 10.1556/650.2021.32157.
3
Annual epidemiological and health insurance disease burden of hip osteoarthritis in Hungary based on nationwide data.基于全国范围内数据的匈牙利髋关节骨关节炎年度流行病学和健康保险疾病负担。
BMC Musculoskelet Disord. 2024 May 23;25(1):406. doi: 10.1186/s12891-024-07513-y.
4
[Epidemiological disease burden and annual health insurance treatment cost of colorectal cancer in Hungary].[匈牙利结直肠癌的流行病学疾病负担及年度医疗保险治疗费用]
Orv Hetil. 2021 Mar 28;162(162 Suppl 1):14-21. doi: 10.1556/650.2021.32152.
5
[Annual epidemiological and health insurance disease burden of pertrochanteric fractures in Hungary].[匈牙利转子间骨折的年度流行病学及健康保险疾病负担]
Orv Hetil. 2021 Mar 28;162(162 Suppl 1):46-53. doi: 10.1556/650.2021.32162.
6
Epidemiological disease burden and annual, nationwide health insurance treatment cost of female infertility based on real-world health insurance claims data in Hungary.基于匈牙利真实世界医疗保险理赔数据的女性不孕症流行病学疾病负担及全国年度医疗保险治疗费用
BMC Health Serv Res. 2025 Mar 4;25(1):336. doi: 10.1186/s12913-025-12348-x.
7
[The nationwide epidemiological and health insurance disease burden of knee and lower leg injuries in Hungary].[匈牙利膝关节和小腿损伤的全国性流行病学及健康保险疾病负担]
Orv Hetil. 2021 Mar 28;162(162 Suppl 1):54-60. doi: 10.1556/650.2021.32160.
8
[Annual epidemiological and health insurance burden of cervical cancer in Hungary].[匈牙利宫颈癌的年度流行病学及健康保险负担]
Orv Hetil. 2021 Mar 28;162(162 Suppl 1):22-29. doi: 10.1556/650.2021.32158.
9
[Epidemiological disease burden and annual health insurance treatment cost of acute myocardial infarction in Hungary].[匈牙利急性心肌梗死的流行病学疾病负担及年度医疗保险治疗费用]
Orv Hetil. 2021 Mar 28;162(162 Suppl 1):6-13. doi: 10.1556/650.2021.32153.
10
[Assessing the epidemiological disease burden and health insurance treatment cost of diabetic polyneuropathy based on health insurance claims data].基于医保理赔数据评估糖尿病性多发性神经病的流行病学疾病负担和医保治疗费用
Orv Hetil. 2021 Mar 28;162(162 Suppl 1):38-45. doi: 10.1556/650.2021.32156.

引用本文的文献

1
Comparative analysis of the quality of life regarding patients who underwent hip replacement in public versus private hospitals in Hungary.比较分析在匈牙利公立医院和私立医院接受髋关节置换手术的患者的生活质量。
Sci Rep. 2024 May 1;14(1):10031. doi: 10.1038/s41598-024-60720-4.
2
Budget impact analysis of an early identification and referral model for diagnosing patients with suspected rheumatoid arthritis in Ireland.爱尔兰类风湿关节炎疑似患者诊断早期识别与转诊模型的预算影响分析
Rheumatol Adv Pract. 2020 Dec 13;4(2):rkaa059. doi: 10.1093/rap/rkaa059. eCollection 2020.
3
Comparative analysis of the economic burdens of physical inactivity in Hungary between 2005 and 2017.

本文引用的文献

1
Changes in the health status of the population of Central and Eastern European countries between 1990 and 2010.1990 年至 2010 年期间中东欧国家人口健康状况的变化。
Eur J Health Econ. 2014 May;15 Suppl 1:S137-41. doi: 10.1007/s10198-014-0602-8. Epub 2014 May 16.
2
[Analysis of health insurance data on home nursing care in Hungary].[匈牙利家庭护理医疗保险数据分析]
Orv Hetil. 2014 Apr 13;155(15):597-603. doi: 10.1556/OH.2014.29842.
3
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
2005 年至 2017 年匈牙利身体活动不足的经济负担比较分析。
BMC Public Health. 2020 Aug 17;20(Suppl 1):1174. doi: 10.1186/s12889-020-08478-y.
利妥昔单抗治疗系统性硬化症的疗效和安全性:来自欧洲硬皮病试验和研究(EUSTAR)组的分析。
Ann Rheum Dis. 2015 Jun;74(6):1188-94. doi: 10.1136/annrheumdis-2013-204522. Epub 2014 Jan 17.
4
Evolution of cost structures in rheumatoid arthritis over the past decade.过去十年类风湿关节炎成本结构的演变。
Ann Rheum Dis. 2015 Apr;74(4):738-45. doi: 10.1136/annrheumdis-2013-204311. Epub 2014 Jan 9.
5
[Social security system for patients with rheumatoid arthritis in Japan].[日本类风湿性关节炎患者的社会保障体系]
Nihon Rinsho. 2013 Jul;71(7):1287-90.
6
Trends in the first decade of 21st century healthcare utilisation in a rheumatoid arthritis cohort compared with the general population.21 世纪第一个十年类风湿关节炎队列患者医疗利用趋势与普通人群比较。
Ann Rheum Dis. 2013 Jul;72(7):1212-6. doi: 10.1136/annrheumdis-2012-202571. Epub 2012 Dec 8.
7
Hungary health system review.匈牙利卫生系统综述。
Health Syst Transit. 2011;13(5):1-266.
8
Medical costs for Korean patients with rheumatoid arthritis based on the national claims database.韩国类风湿关节炎患者的医疗费用:基于国家索赔数据库的研究。
Rheumatol Int. 2012 Sep;32(9):2893-9. doi: 10.1007/s00296-011-2117-2. Epub 2011 Sep 7.
9
Challenges in economic evaluation of new drugs: experience with rituximab in Hungary.新药经济评估中的挑战:匈牙利利妥昔单抗的经验。
Med Sci Monit. 2010 Jan;16(1):SR1-5.
10
Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment.与类风湿关节炎相比,银屑病关节炎的疾病负担,匈牙利实验。
Rheumatol Int. 2009 Dec;30(2):199-205. doi: 10.1007/s00296-009-0936-1.